<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062113</url>
  </required_header>
  <id_info>
    <org_study_id>A3191200</org_study_id>
    <nct_id>NCT01062113</nct_id>
  </id_info>
  <brief_title>Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter, Comparative Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In The Treatment Of Acute Pain After Oral Surgery Lateral Mandibular Impacted Third Molar Tooth Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of additional dose of celecoxib, as compared to placebo, in
      patients with post lateral mandibular impacted third molar tooth extraction pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Rate (Percentage) of Patient's Impression</measure>
    <time_frame>2 hours post-additional dose</time_frame>
    <description>Patient's impression was assessed by self-report and was entered in the patient diary, based on the following categories: &quot;Excellent&quot;, &quot; Good&quot;, &quot;Fair&quot; and &quot;Poor&quot;.
Efficacy rate was calculated from the following formula, &quot;The number of participants assessed as Excellent or Good&quot; over &quot;total participants&quot; multiplied by 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Pain Intensity (PI) With 4 Categories</measure>
    <time_frame>2 hours after additional dose</time_frame>
    <description>Pain intensity was entered in the patient diary on the following categories: &quot;No pain&quot;, &quot;Mild pain&quot;, &quot;Moderate pain&quot; and &quot;Severe pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Measured by Visual Analog Scale (VAS)</measure>
    <time_frame>2 hours post-additional dose</time_frame>
    <description>The Pain intensity was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=unbearable maximal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Pain Intensity (PI) Measured by VAS Among Participants</measure>
    <time_frame>Pre-additional dose (baseline) and 2 hours post-additional dose</time_frame>
    <description>The differences in PI were obtained by subtracting the PI at each time point from the Baseline PI score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Celecoxib 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with &quot;moderate pain&quot; or &quot;severe pain&quot;rated as 45.0 mm or more on the VAS</description>
    <arm_group_label>Celecoxib 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain</description>
    <arm_group_label>Celecoxib 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Initial dose:

          -  20 to 64 years

          -  Patients with undergoing mandibular impacted third molar tooth extraction accompanied
             by lateral bone removal and crown cutting

          -  Patients with pain that meets both of the following criteria

          -  Pain intensity (4-categorical): &quot;moderate pain&quot; or &quot;severe pain&quot;

          -  Pain intensity (VAS): 45.0 mm or more

        Additional dose:

          -  Patients with pain that corresponds to &quot;4. Agree&quot; or &quot;5. Strongly agree&quot; as the answer
             to the &quot;question about the pain intensity&quot; during the period from 5 hours to 12 hours
             post-initial dose of the study drug

        Exclusion Criteria:

          -  Patients with acute inflammatory findings in the oral cavity necessitating treatment

          -  Patients who are scheduled to receive general anesthesia and analgesics in the process
             of the eligible tooth extraction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jyuzen General Hospital</name>
      <address>
        <city>Niihama-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Dental College Hospital</name>
      <address>
        <city>Kitakyusyu-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bishinkai Medical Corporation Health Park Clinic</name>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kure Kyosai Hospital</name>
      <address>
        <city>Kure-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa Medical Center</name>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa University Faculty of Medicine University Hospital</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Medical Center</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Medical Center</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maruko Central General Hospital</name>
      <address>
        <city>Ueda-shi</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagano National Hospital</name>
      <address>
        <city>Ueda-shi</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Nippon Dental University Niigata Hospital</name>
      <address>
        <city>Niigata-shi</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Dental University Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Prefectural General Medical Center</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meikai University Hospital</name>
      <address>
        <city>Sakado-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Medical Center</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi National Hospital</name>
      <address>
        <city>Utsunomiya-shi</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hachioji Hospital</name>
      <address>
        <city>Hachiouji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Red Cross Musashino Hospital</name>
      <address>
        <city>Musashino-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Dental Hospital</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Medical Center NTT EC</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191200&amp;StudyName=Study%20To%20Evaluate%20Efficacy%20And%20Safety%20Of%20An%20Additional%20Dose%20Of%20Celecoxib%20%28YM177%29%20In%20Patients%20With%20Post-Tooth%20Extraction%20Pain</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <results_first_submitted>August 1, 2011</results_first_submitted>
  <results_first_submitted_qc>October 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2012</results_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute pain after oral surgery lateral mandibular Impacted third molar tooth extraction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Initial Dose Celecoxib 400 mg</title>
          <description>Included the participants who received initial dose of celecoxib 400 mg only</description>
        </group>
        <group group_id="P2">
          <title>Additional Dose Celecoxib 200 mg</title>
          <description>Included participants who received celecoxib 200 mg as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
        </group>
        <group group_id="P3">
          <title>Additional Dose Placebo</title>
          <description>Included participants who received placebo as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initial Dose Celecoxib 400 mg</title>
          <description>Included the participants who received initial dose of celecoxib 400 mg only</description>
        </group>
        <group group_id="B2">
          <title>Additional Dose Celecoxib 200 mg</title>
          <description>Included participants who received celecoxib 200 mg as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
        </group>
        <group group_id="B3">
          <title>Additional Dose Placebo</title>
          <description>Included participants who received placebo as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Rate (Percentage) of Patient’s Impression</title>
        <description>Patient’s impression was assessed by self-report and was entered in the patient diary, based on the following categories: &quot;Excellent&quot;, &quot; Good&quot;, &quot;Fair&quot; and &quot;Poor&quot;.
Efficacy rate was calculated from the following formula, &quot;The number of participants assessed as Excellent or Good&quot; over &quot;total participants&quot; multiplied by 100.</description>
        <time_frame>2 hours post-additional dose</time_frame>
        <population>The full analysis set (FAS). This analysis set consisted of randomized participants who received the additional dose of the study drug and who were assessed for at least one efficacy endpoint after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Dose Celecoxib 200 mg</title>
            <description>Included participants who received celecoxib 200 mg as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
          <group group_id="O2">
            <title>Additional Dose Placebo</title>
            <description>Included participants who received placebo as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Rate (Percentage) of Patient’s Impression</title>
          <description>Patient’s impression was assessed by self-report and was entered in the patient diary, based on the following categories: &quot;Excellent&quot;, &quot; Good&quot;, &quot;Fair&quot; and &quot;Poor&quot;.
Efficacy rate was calculated from the following formula, &quot;The number of participants assessed as Excellent or Good&quot; over &quot;total participants&quot; multiplied by 100.</description>
          <population>The full analysis set (FAS). This analysis set consisted of randomized participants who received the additional dose of the study drug and who were assessed for at least one efficacy endpoint after randomization.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The difference in the efficacy rates was tested using normal distribution at a significance level of 2-sided 5%. 2-sided 95% confidence interval (CI) for the difference in the efficacy rates was calculated using normal approximation.</p_value_desc>
            <method>asymptotic z-test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>38.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.3</ci_lower_limit>
            <ci_upper_limit>56.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Pain Intensity (PI) With 4 Categories</title>
        <description>Pain intensity was entered in the patient diary on the following categories: &quot;No pain&quot;, &quot;Mild pain&quot;, &quot;Moderate pain&quot; and &quot;Severe pain&quot;.</description>
        <time_frame>2 hours after additional dose</time_frame>
        <population>The full analysis set (FAS), Baseline Observation Carried Forward (BOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Dose Celecoxib 200mg</title>
            <description>Included participants who received Celecoxib 200 mg as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
          <group group_id="O2">
            <title>Additional Dose Placebo</title>
            <description>Included participants who received placebo as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Pain Intensity (PI) With 4 Categories</title>
          <description>Pain intensity was entered in the patient diary on the following categories: &quot;No pain&quot;, &quot;Mild pain&quot;, &quot;Moderate pain&quot; and &quot;Severe pain&quot;.</description>
          <population>The full analysis set (FAS), Baseline Observation Carried Forward (BOCF).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Measured by Visual Analog Scale (VAS)</title>
        <description>The Pain intensity was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=unbearable maximal pain.</description>
        <time_frame>2 hours post-additional dose</time_frame>
        <population>The full analysis set (FAS), Baseline Observation Carried Forward (BOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Dose Celecoxib 200 mg</title>
            <description>Included participants who received celecoxib 200 mg as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
          <group group_id="O2">
            <title>Additional Dose Placebo</title>
            <description>Included participants who received placebo as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Measured by Visual Analog Scale (VAS)</title>
          <description>The Pain intensity was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=unbearable maximal pain.</description>
          <population>The full analysis set (FAS), Baseline Observation Carried Forward (BOCF).</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="25.5"/>
                    <measurement group_id="O2" value="51.9" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Pain Intensity (PI) Measured by VAS Among Participants</title>
        <description>The differences in PI were obtained by subtracting the PI at each time point from the Baseline PI score.</description>
        <time_frame>Pre-additional dose (baseline) and 2 hours post-additional dose</time_frame>
        <population>The full analysis set (FAS), Baseline Observation Carried Forward (BOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Dose Celecoxib 200 mg</title>
            <description>Included participants who received celecoxib 200 mg as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
          <group group_id="O2">
            <title>Additional Dose Placebo</title>
            <description>Included participants who received placebo as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Pain Intensity (PI) Measured by VAS Among Participants</title>
          <description>The differences in PI were obtained by subtracting the PI at each time point from the Baseline PI score.</description>
          <population>The full analysis set (FAS), Baseline Observation Carried Forward (BOCF).</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" spread="24.2"/>
                    <measurement group_id="O2" value="12.3" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent to Day 28 postdose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Initial Dose Celecoxib 400 mg</title>
          <description>Included the participants who received initial dose of celecoxib 400 mg only</description>
        </group>
        <group group_id="E2">
          <title>Additional Dose Celecoxib 200 mg</title>
          <description>Included participants who received celecoxib 200 mg as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
        </group>
        <group group_id="E3">
          <title>Additional Dose Placebo</title>
          <description>Included participants who received placebo as an additional dose from 5 to 12 hours after the initial dose (celecoxib 400 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Beta 2 microglobulin increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Beta-N-acetyl-D-glucosaminidase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urobilin urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer Clinical Trials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

